HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stoppi... by HPS2-THRIVE Collaborative Group, Jiang, L, Hopewell, J, Collins, R, Armitage, J

Serious adverse effects of extended-release niacin/laropiprant: results from the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE)... by Haynes, R, Valdes-Marquez, E, Hopewell, JC, Chen, F, Li, J, Parish, S, Landray, MJ, Armitage, J, Hps2-Thrive Collaborative Group

Investigating modifications to participant information materials to improve recruitment into a large randomized trial. by HPS2-THRIVE Collaborative Group, Haynes, R, Chen, F, Wincott, E, Dayanandan, R, Lay, MJ, Parish, S, Bowman, L, Landray, MJ, Armitage, J

Investigating modifications to participant information materials to improve recruitment into a large randomized trial by The HPS2-THRIVE Collaborative Group, Richard Haynes, Fang Chen, Elizabeth Wincott, Rejive Dayanandan, Michael J. Lay, Sarah Parish, Louise Bowman, Martin J. Landray, Jane Armitage

Get full text